Meningococcal serogroup C conjugate vaccine

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• Meningococcal meningitis and septicaemia pose significant global health risks, primarily caused by serogroups A, B, and C.
• An increase in meningococcal serogroup (MS) C disease was observed in the UK and Europe during the late 1990s.
• Existing polysaccharide MS C vaccines were less effective in infants under two years old.

Purpose of the Study:

• To evaluate the immunogenicity, safety, and efficacy of Meningitec, a novel conjugate vaccine against meningococcal serogroup C disease.
• To assess the potential for long-term protection induced by the conjugate vaccine.

Main Methods:

• Meningitec, a conjugate vaccine combining serogroup C oligosaccharide with CRM197 protein, was administered to infants, toddlers, children, and adults.
• Immunogenicity was assessed by measuring immune responses.
• Surveillance studies monitored disease incidence post-vaccine introduction.
• Safety was evaluated through pre-licensure research and post-licensure adverse event data.

Main Results:

• Meningitec demonstrated immunogenicity across all tested age groups, including infants.
• The vaccine was shown to induce immunological memory, suggesting potential for long-term protection.
• Post-introduction surveillance revealed a dramatic decrease in MS C disease incidence.
• Pre-licensure and post-licensure data confirmed the vaccine's safety profile.

Conclusions:

• Meningitec is an effective and safe conjugate vaccine for preventing meningococcal serogroup C disease in all age groups.
• The vaccine's ability to induce immunological memory supports its role in providing long-term protection.
• The widespread use of Meningitec has significantly reduced the burden of MS C disease.